Researchers have revealed that hydroxyurea significantly reduces infections in children with sickle cell anemia. Their findings enhance strong evidence of hydroxyurea's effectiveness and could ...

Hydroxyurea remains effective over the long term among children with sickle cell disease, real-world data suggested. The average time on hydroxyurea was 5 years, with many children on the therapy for ...

Few youths with sickle cell anemia (SCA) receive hydroxyurea despite national guidelines recommending its use, according to a study published online March 24 in JAMA Network Open. Sarah L. Reeves, ...

Clinical research led by Indiana University School of Medicine investigators and their collaborators in Uganda has revealed that hydroxyurea significantly reduces infections in children with sickle ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported a mean annual days’ supply of hydroxyurea of 47.2 days per child in Michigan and 97.4 days ...

SAN DIEGO -- Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in patients with hemoglobin SC, a milder form of sickle cell disease (SCD), a ...

Painful symptoms of sickle-cell disease begin within the first year of life. Hydroxyurea (hydroxycarbamide) has been shown to reduce pain in adults (N Engl J Med. 1995;332:1317-1322) and has been ...

For girls with sickle cell disease, density of growing follicles was marginally lower in hydroxyurea group after adjustment for age. HealthDay News — For girls and young women with sickle cell disease ...

Please provide your email address to receive an email when new articles are posted on . Use of hydroxyurea did not reduce ovarian reserve among girls and young women with sickle cell disease.

Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...

Zinc for Infection Prevention in Sickle Cell Anemia study leaders Chandy John, far left; Ruth Namazzi, second from right; and Robert Opoka, far right; with Justin Brown, second from left, and Aaron ...